Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

Vaccine development - 25/05/2021

Vaccines - a beacon of hope in the fight against pandemics

Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.

Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus.

Project REVeyeVE - 06/02/2025

Targeted, virus-free gene therapy for the eye using degradable nanopropellers

Eye diseases that result in blindness in young people are primarily caused by genetic mutations. An interdisciplinary team of researchers from the Universities of Tübingen and Heidelberg is developing an innovative gene therapy method using biodegradable, magnetic nanopropellers. These innovative nanopropellers can effectively deliver intact genes into the affected cells, offering a potential solution for treating genetic disorders of this kind.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on mRNA, today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.

A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.

Inside the fight against COVID-19 - 28/10/2020

A new immunotherapeutic agent for treating severe COVID-19 cases

Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defence and antiviral drugs by becoming "latent". In this state, they are largely invisible and unassailable. As long as these dormant viruses persist, there is no cure for HIV/AIDS. However, researchers at Ulm University Hospital have discovered a new way to reactivate latent HI viruses.

PixelBiotech GmbH - 27/07/2021

Searching for tracks with cytogenetics and AI

The startup Pixelbiotech combines fluorescence techniques with artificial intelligence to detect DNA and RNA in medical samples. HuluFISH is the name of the method, which allows for countless applications - from detecting viral infections, such as COVID-19 or African swine fever virus, to the quality control of gene and immunotherapeutic procedures in cancer medicine.

Immune complexes in COVID-19 - 01/03/2023

Vicious circle of hyperinflammation

Whether a person experiences only a mild malaise or a critical course of disease after a coronavirus infection apparently depends on the antigen-antibody complexes that form in our body. The discovery of these immune complexes set a group of researchers, headed up by Prof. Dr. Hartmut Hengel from the Freiburg University Medical Centre, on the trail of a vicious circle of constantly escalating inflammation.

Viral zoonoses - 24/01/2022

Development of inhibitors that help stop viral zoonoses

Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.

Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

Dossier - 01/04/2013

Retroviruses from infectious agent to therapeutic assistant

Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV. However retroviruses are not only of interest for researchers looking for effective cures for viral infections their characteristic properties also make them promising laboratory and gene therapy tools.

In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors.

Dossier - 05/11/2012

Cancer basic research successes and trends

Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.

Federal government awards 3.5 million euros in funding to the collaborative research project FLU-PREP. Researchers are developing methods to identify the pandemic potential of new viruses at an early stage.